COMMUNIQUÉS West-GlobeNewswire

SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals
02/10/2026
Major Institutional Formulary Win Expands Arbli ™ ’s Presence in Pediatric Care as Wholesale Orders Continue to Increase Sequentially Arbli ™ Addresses an Approximately $219 Million U.S. Losartan Market Representing [...]
Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026
02/10/2026
Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Century's iPSC-derived islet replacement therapy for type 1 diabetes CNTY-813 IND [...]
20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026
02/10/2026
Management to Hold One-on-One Meetings with Institutional Investors at the Hard Rock Hotel New York GAITHERSBURG, Md., Oct. 02, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (the “Company”), an early [...]
LifeWorks Wellness Center Opens New Facility, Centralizing Care on Main Campus in Clearwater
02/10/2026
CLEARWATER, Fla., Oct. 02, 2026 (GLOBE NEWSWIRE) -- LifeWorks Wellness Center will celebrate the opening of its new treatment facility at 375 Turner Street, located immediately adjacent to its main clinic, with a public [...]
Cuprina (Nasdaq: CUPR) to Acquire EBITDA-Positive Seven-Clinic Singapore Healthcare Group
02/10/2026
Acquiring 100% of East Coast Podiatry (five clinics) and Orchard Clinic (two clinics) for approximately S$4.0 million (approximately US$3.1 million) Target Group generated FY2025 unaudited revenue of approximately S$9.1 [...]
iTonic Holdings Ltd Announces 16-for-1 Share Consolidation Effective October 6, 2026
02/10/2026
BEIJING, China, Oct. 02, 2026 (GLOBE NEWSWIRE) -- iTonic Holdings Ltd (Nasdaq: ITOC) (the “Company”), a healthcare company developing digital medical technologies, today announced that at the extraordinary general [...]
MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026
02/10/2026
agenT-797 enables tumor-cell killing in a human relevant model of checkpoint inhibitor–resistant colorectal cancer liver metastases Native and engineered iNKT cells eliminate senescent tumor cells and fibroblasts in [...]
Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
02/10/2026
- Atebimetinib enhances PD-1 checkpoint blockade in preclinical models of RAS mutant tumors - - Findings provide additional mechanistic rationale for upcoming Phase 2 study of atebimetinib in combination with PD-1 [...]
Candel Therapeutics to Present at the SITC 2026 Annual Meeting
02/10/2026
NEEDHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve [...]
ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026
02/10/2026
Seven abstracts spanning CKD translational model studies and drug product characterization provide converging evidence supporting a multifactorial mechanism of action for rilparencel One clinical abstract presents a new [...]
Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
02/10/2026
New immune data from the phase 2 trial with EVX-01 to be presented both in an oral and poster presentation New data follows from the three-year clinical update for EVX-01 to be provided at the European Society for [...]
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026
02/10/2026
Oral presentation highlighting updated clinical data from at least 20 patients with refractory rheumatoid arthritis (RA), 11 patients with Sjögren disease (SjD) and at least five patients with systemic sclerosis (SSc) [...]
Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026
02/10/2026
BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that there will be multiple presentations at the American Society of [...]
Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
02/10/2026
Preliminary Phase 2 data from the ongoing PrisMN study of budoprutug in primary membranous nephropathy selected for oral presentation Presentations on CLYM116 and budoprutug programs highlight advancements across the [...]
SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026
02/10/2026
DENVER, Oct. 02, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure [...]
CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026
02/10/2026
ZUG, Switzerland and BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation highlighting the Company’s Phase 1 clinical data of its investigational [...]
Completion of share buyback programme
02/10/2026
ANNOUNCEMENT NO. 316 2 October 2026 ChemoMetec A/S has completed the share buyback programme announced in company announcement no. 309 dated 15 May 2026. The programme provided for the repurchase of up to 500,000 shares [...]
Guidepoint Qsight Reports Male Neurotoxin Spending Exceeds $500 Per Visit for the First Time
02/10/2026
New York, USA, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Males Spend Also Outweighs Women’s Qsight patient transaction data shows male neurotoxin average spend per transaction in Q3-to-date at $529, the highest Qsight has ever [...]
European Medicines Agency Validates Biosplice’s Application for Lorecivivint (LOR) in Knee Osteoarthritis and Begins Review
02/10/2026
LOR is now under regulatory review in both the United Kingdom and the European Union SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a late-stage biopharmaceutical company [...]

Pages